Optimization of Exenatide plus Detemir Treatment for Morbid Obese Patients with Insulin Dependent Diabetes Resistant to Conventional Treatment. Effect of Exenatide on Patients with Mellitus Diabetes Type 2

• 作者: Alfonso López Ruiz Amparo Meoro Avilés Collaborative Groups of the Diabetes and Obesity Unit of the Hospital Reina Sofía Cristina del Peso Gilsanz José Soriano Palao María ángeles Nú?ez Sánchez María Dolores Ortu?o María Teresa Gallego García Noelia Victoria García-Talavera Espín Ricardo Soriano Sánchez Sacramento Tomás Navarro
• 来源期刊: 药理与制药(英文)
• 学科: 医学
• 关键词: TYPE 2 DIABETES MELLITUS EXENATIDE Cardiovascular Risk Physical and Biochemical Parameters
• 年，卷（期）: 2014,（4）
• 页码范围: 433-443
• 页数: 11页
• 分类号: R5

摘要

The purpose of this study was to analyze the effects of the treatment with Exenatide joint to insulin detemir. The study was carried out with obese patients with type 2 diabetes mellitus (DM2) and deficient control, despite intensive insulin therapy combined with oral antidiabetics. A longitudinal study was made with 15 patients controlled by the Endocrinology and Nutrition Section of the Reina Sofía University Hospital, Murcia. These patients were treated with Exenatide joint to insulin during 3, 6 and 12 months. Statistically meaningful differences (p < 0.05) were observed in the reduction of HbA1c in the 3 and 6 months treatment groups (initial HbA1c: 9.55% ± 1.086%, weight: 119.94 kg, insulin requirement: 0.71 IU/kg/day;after 3 months: HbA1c: 7.77% ± 1.164%, weight: 98.13 kg, insulin requirement: 0.59 IU/kg/day;after 6 months: HbA1c: 7.21%, weight: 97.93 kg, insulin requirement: 0.55 IU/kg/day). It was observed that the association of Exenatide and insulin promotes an improvement in several indicators such as weight, body mass index (BMI), systolic pressure (SP), diastolic pressure (DP), triglycerides (TG), cLDL, cHDL and total cholesterol (TC), in patients with diabetes resistant to conventional therapy. However, these improvements were statistically no significant (p < 0.05). It is possible to talk of a reduction of cardiovascular risk factors in patients with Exenatide, being thus a suitable option for this kind of individuals. It is important to emphasize the fact that our study showed bigger body-weight reductions results after 6 and 12 months, as compared to the researches quoted.